secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268815
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports Q3 net loss $52.9M; initiates Phase 2 HS trial, receives $40M milestone
--------------------------------------------------------------------------------

- Net loss of $52.9M in Q3 2023 vs $43.0M loss in Q3 2022; revenue $4.7M down from $9.6M.
- First patient dosed in KT-474 (IRAK4) Phase 2 HS trial triggered $40M milestone from Sanofi; Phase 2 AD dosing expected Q4 2023.
- KT-333 (STAT3) Phase 1 shows partial response in CTCL patient; Fast Track granted for CTCL/PTCL.
- KT-253 (MDM2) achieved proof-of-mechanism; confirmed partial response in Merkel cell carcinoma patient.
- KT-413 (IRAKIMiD) development discontinued; cash $435M provides runway into H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/0001193125-23-268815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/d579034d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer